晨光生物 reported revenue of ¥3.16B for the period ended 2026-06-30, -13.6% year on year. Net income was ¥0.18B, a 5.8% net margin on a 13.5% gross margin. The largest revenue line is 色素/香辛料/甜味剂/营养及药用类产品 at 51% of the total. Free cash flow for the period was ¥0.91B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥3.16B | -13.6% |
| Gross profit | ¥0.43B | — |
| Operating income | ¥0.21B | — |
| Net income | ¥0.18B | -16.7% |
| Gross margin | 13.5% | Net margin 5.8% |
| Revenue Q/Q | -6.1% | — |
| Segment | Revenue | Share |
|---|---|---|
| 色素/香辛料/甜味剂/营养及药用类产品 | ¥1.62B | 51.2% |
| 棉籽类业务 | ¥1.38B | 43.7% |
| 其他 | ¥0.16B | 5.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥2.73B | 86.5% |
| R&D | ¥0.07B | 2.2% |
| SG&A | ¥0.10B | 3.2% |
| Tax & other | ¥0.03B | 0.8% |
| Item | Amount |
|---|---|
| Total assets | ¥9.62B |
| Total liabilities | ¥6.16B |
| Shareholders' equity | ¥3.46B |
| Equity / assets | 35.9% |
| Operating cash flow | ¥0.94B |
| Capital expenditure | ¥0.03B |
| Free cash flow | ¥0.91B |
| Cash conversion (OCF / net income) | 661% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
晓程科技 ・ 节能环境 ・ 和顺电气 ・ 沃森生物 ・ 盈康生命 ・ 宋城演艺 ・ 南方泵业 ・ 汤臣倍健 ・ *ST香雪 ・ 天舟文化 ・ 睿智医药 ・ 世纪瑞尔
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies